Chandler DB - Search Results

1

Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.

Fust K, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH. Fust K, et al. Among authors: chandler db. Gynecol Oncol. 2014 Jun;133(3):446-53. doi: 10.1016/j.ygyno.2014.03.014. Epub 2014 Mar 19. Gynecol Oncol. 2014. PMID: 24657302

2

Cost per response analysis of strategies for chronic immune thrombocytopenia.

Fust K, Parthan A, Li X, Sharma A, Zhang X, Campioni M, Lin J, Wang X, Zur R, Cetin K, Eisen M, Chandler D. Fust K, et al. Am J Manag Care. 2018 Jul;24(8 Spec No.):SP294-SP302. Am J Manag Care. 2018. PMID: 30020741 Free article.

3

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.

Weycker D, Doroff R, Hanau A, Bowers C, Belani R, Chandler D, Lonshteyn A, Bensink M, Lyman GH. Weycker D, et al. BMC Cancer. 2019 Aug 9;19(1):792. doi: 10.1186/s12885-019-6010-9. BMC Cancer. 2019. PMID: 31399079 Free PMC article.

4

Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population.

Kawatkar AA, Farias AJ, Chao C, Chen W, Barron R, Vogl FD, Chandler DB. Kawatkar AA, et al. Among authors: chandler db. Support Care Cancer. 2017 Sep;25(9):2787-2795. doi: 10.1007/s00520-017-3692-x. Epub 2017 Apr 10. Support Care Cancer. 2017. PMID: 28397022 Free PMC article.

5

Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice.

Weycker D, Chandler D, Barron R, Xu H, Wu H, Edelsberg J, Lyman GH. Weycker D, et al. J Oncol Pharm Pract. 2017 Jan;23(1):33-42. doi: 10.1177/1078155215614997. Epub 2016 Jul 9. J Oncol Pharm Pract. 2017. PMID: 26568602

6

Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data.

Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D. Bonafede M, et al. Among authors: chandler d. Arch Osteoporos. 2016 Dec;11(1):26. doi: 10.1007/s11657-016-0280-5. Epub 2016 Jul 30. Arch Osteoporos. 2016. PMID: 27475642 Free PMC article.

7

Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.

Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D. Weycker D, et al. Curr Med Res Opin. 2017 Dec;33(12):2107-2113. doi: 10.1080/03007995.2017.1386858. Epub 2017 Oct 16. Curr Med Res Opin. 2017. PMID: 28958157

8

Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims.

Weycker D, Hanau A, Lonshteyn A, Bowers C, Bensink M, Garawin T, Chandler D. Weycker D, et al. Curr Med Res Opin. 2018 Sep;34(9):1705-1711. doi: 10.1080/03007995.2018.1495621. Epub 2018 Jul 25. Curr Med Res Opin. 2018. PMID: 29962268

9

Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries.

Yusuf AA, Matlon TJ, Grauer A, Barron R, Chandler D, Peng Y. Yusuf AA, et al. Arch Osteoporos. 2016 Dec;11(1):31. doi: 10.1007/s11657-016-0285-0. Epub 2016 Sep 30. Arch Osteoporos. 2016. PMID: 27696099

10

Predictors of imminent risk of fracture in Medicare-enrolled men and women.

Yusuf AA, Hu Y, Chandler D, Crittenden DB, Barron RL. Yusuf AA, et al. Among authors: chandler d. Arch Osteoporos. 2020 Aug 3;15(1):120. doi: 10.1007/s11657-020-00784-7. Arch Osteoporos. 2020. PMID: 32748034 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters